Retina Consultants of Texas

Running trials

• Recruiting

  A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).

  NCT07867080· Phase 3· 4D Molecular Therapeutics· Source

• Recruiting

  A Study in Adults With Geographic Atrophy

  NCT07606365· Phase 2· Sitala Bio LTD· Source

• Recruiting

  A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)

  NCT07705555· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Longitudinal Study of Retinal Function in Eyes Treated for Diabetic Macular Edema With Anti-VEGF Agents

  NCT07567833· Phase 4· Jaeb Center for Health Research· Source

• Recruiting

  A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

  NCT07614776· Phase 3· Amgen· Source

• Recruiting

  A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated

  NCT07553429· Phase 1/2· Boehringer Ingelheim· Source

• Recruiting

  A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)

  NCT07496567· Phase 2/3· EyeBiotech Ltd.· Source

• Recruiting

  A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

  NCT07441642· Phase 2· Novartis Pharmaceuticals· Source

• Enrolling by invitation

  Long-Term Follow Up of VOY-101 Non-nAMD Extension Study

  NCT07660640· Perceive Biotherapeutics, Inc.· Source

• Active, not recruiting

  COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

  NCT07449936· Phase 3· EyePoint Pharmaceuticals, Inc.· Source

• Active, not recruiting

  CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

  NCT07449923· Phase 3· EyePoint Pharmaceuticals, Inc.· Source

• Recruiting

  Neoadjuvant Darovasertib in Primary Uveal Melanoma

  NCT07015190· Phase 3· IDEAYA Biosciences· Source

• Active, not recruiting

  High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes

  NCT07118670· Phase 4· Edward Wood, MD· Source

• Recruiting

  Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

  NCT07007065· Phase 3· AbbVie· Source

• Recruiting

  Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

  NCT06659445· Phase 2· ONL Therapeutics· Source

• Recruiting

  A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

  NCT07215234· Phase 1/2· Sanofi· Source

• Recruiting

  A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)

  NCT07161544· Phase 1/2· AAVantgarde Bio Srl· Source

• Recruiting

  Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR

  NCT06790784· Phase 3· Jaeb Center for Health Research· Source

• Recruiting

  A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)

  NCT06557460· Phase 2· Regenerative Patch Technologies, LLC· Source

• Recruiting

  A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK

  NCT06990399· Phase 3· Kodiak Sciences Inc· Source

• Recruiting

  A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE

  NCT06996080· Phase 3· Kodiak Sciences Inc· Source

• Recruiting

  A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

  NCT07215390· Phase 2· Apellis Pharmaceuticals, Inc.· Source

• Active, not recruiting

  Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)

  NCT06912633· Phase 2· jCyte, Inc· Source

• Recruiting

  A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema

  NCT06962839· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD

  NCT06346600· Skyline Therapeutics· Source

• Active, not recruiting

  A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT06795048· Phase 4· Hoffmann-La Roche· Source

• Active, not recruiting

  4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

  NCT06864988· Phase 3· 4D Molecular Therapeutics· Source

• Active, not recruiting

  Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration

  NCT06495918· Phase 3· Ocular Therapeutix, Inc.· Source

• Active, not recruiting

  A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

  NCT06683742· Phase 3· EyePoint Pharmaceuticals, Inc.· Source

• Recruiting

  A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

  NCT06541704· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56

  NCT06668064· Phase 3· EyePoint Pharmaceuticals, Inc.· Source

• Recruiting

  A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  NCT06635148· Phase 2/3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

  NCT06556368· Phase 3· Kodiak Sciences Inc· Source

• Active, not recruiting

  Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)

  NCT06550011· Phase 1/2· Avirmax Biopharma Inc· Source

• Active, not recruiting

  A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

  NCT06510816· Phase 3· Annexon, Inc.· Source

• Active, not recruiting

  A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

  NCT06491914· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)

  NCT06445322· Ascidian Therapeutics, Inc· Source

• Active, not recruiting

  A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa

  NCT06388200· Phase 3· Ocugen· Source

• Active, not recruiting

  Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

  NCT06467344· Phase 1/2· Ascidian Therapeutics, Inc· Source

• Active, not recruiting

  ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

  NCT06373731· Phase 3· Stealth BioTherapeutics Inc.· Source

• Recruiting

  A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

  NCT06321302· Phase 2· Boehringer Ingelheim· Source

• Active, not recruiting

  A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

  NCT04850118· Phase 2/3· Beacon Therapeutics· Source

• Recruiting

  Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)

  NCT05986864· Phase 1/2· Skyline Therapeutics (US) Inc.· Source

• Active, not recruiting

  Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration

  NCT06223958· Phase 3· Ocular Therapeutix, Inc.· Source

• Active, not recruiting

  Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema

  NCT06116916· Phase 2· Kyowa Kirin Co., Ltd.· Source

• Active, not recruiting

  Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

  NCT05904028· Phase 3· Jaeb Center for Health Research· Source

• Active, not recruiting

  Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy

  NCT06018558· Phase 1/2· Ocugen· Source

• Active, not recruiting

  A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

  NCT06161584· Apellis Pharmaceuticals, Inc.· Source

• Active, not recruiting

  A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease

  NCT05956626· Phase 2/3· Ocugen· Source

• Active, not recruiting

  Evaluation of Tonabersat for DME

  NCT05727891· Phase 2· Jaeb Center for Health Research· Source

Showing 50 of 62.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Macular degeneration28 recruiting
• Diabetic eye disease6 recruiting
• Melanoma1 recruiting
• Retinitis pigmentosa1 recruiting

Closed trials

• Completed

  Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe

  NCT07214740· Phase 3· Apellis Pharmaceuticals, Inc.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

  NCT06270836· Phase 3· Kodiak Sciences Inc· Source

• Completed

  Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)

  NCT05989126· Phase 3· Regeneron Pharmaceuticals· Source

• Completed

  A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)

  NCT06172257· Phase 3· Oculis· Source

• Completed

  Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

  NCT06116890· Phase 2· Kyowa Kirin Co., Ltd.· Source

• Completed

  A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

  NCT06006585· Phase 1· Boehringer Ingelheim· Source

• Completed

  Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema

  NCT05697809· Phase 2· Oxular Limited· Source

• Terminated

  Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

  NCT05893537· Phase 2· Cognition Therapeutics· Source

• Completed

  Safety and Efficacy of Faricimab in Patients With NPDR

  NCT05681884· Phase 2· Greater Houston Retina Research· Source

• Completed

  A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

  NCT05839041· Phase 2· Aviceda Therapeutics, Inc.· Source

• Completed

  A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  NCT05811351· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration

  NCT05643118· Phase 1· Olix Pharmaceuticals, Inc.· Source

• Completed

  Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

  NCT05536297· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Completed

  Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema

  NCT05512962· Phase 2· Oxular Limited· Source

• Completed

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema

  NCT06850922· Phase 1/2· Genentech, Inc.· Source

• Completed

  Safety and Efficacy of AM712 in Patients with NAMD

  NCT05345769· Phase 1· AffaMed Therapeutics Limited· Source

• Completed

  Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration (i-SIGHT)

  NCT05447650· i-Lumen Scientific, Inc.· Source

• Terminated

  Aqueous Biomarker Levels in Diabetic Retinopathy and Diabetic Macular Edema

  NCT05333055· Greater Houston Retina Research· Source

• Completed

  A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema

  NCT05151731· Phase 2· Hoffmann-La Roche· Source

• Completed

  A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema

  NCT05151744· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

  NCT05197270· Phase 1/2· 4D Molecular Therapeutics· Source

• Completed

  A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

  NCT04740671· Phase 3· Shanghai Henlius Biotech· Source

• Completed

  Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial

  NCT04708145· Phase 4· Greater Houston Retina Research· Source

• Completed

  A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT04777201· Phase 3· Hoffmann-La Roche· Source

• Completed

  An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD

  NCT04770545· Phase 3· Apellis Pharmaceuticals, Inc.· Source

• Completed

  RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)

  NCT04832724· Phase 2· AbbVie· Source

• Completed

  Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

  NCT04671433· Phase 3· MeiraGTx Ocular UK Ltd· Source

• Completed

  Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration

  NCT04567303· Phase 1/2· Hoffmann-La Roche· Source

• Terminated

  HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

  NCT04566445· Phase 2· Gyroscope Therapeutics Limited· Source

• Completed

  A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm

  NCT04503551· Phase 3· Hoffmann-La Roche· Source

• Completed

  Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

  NCT04417530· Phase 2· Aura Biosciences· Source

• Completed

  A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema

  NCT04527107· Phase 2· Oxurion· Source

• Completed

  Comparative Study of Dexamethasone Implant to Intravitreal Aflibercept in Subjects With Diabetic Macular Edema

  NCT04411693· Phase 4· The Cleveland Clinic· Source

• Terminated

  GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)

  NCT03894020· Gyroscope Therapeutics Limited· Source

• Recruiting

  Extension Study for the Port Delivery System With Ranibizumab (Portal)

  NCT03683251· Phase 3· Hoffmann-La Roche· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Macular degeneration28 works · 56 trials
• Diabetic eye disease20 works · 32 trials